About

Dr. Joseph Benevenia is a graduate of New Jersey Medical School and completed his orthopaedic residency at University Hospital. He further specialized through a fellowship in Orthopaedic Oncology/Pathology at Case Western Reserve University. His areas of interest include musculoskeletal oncology and limb salvage surgeries, with a focus on bone and soft-tissue tumors, allograft and endoprosthetic reconstructions, and limb-salvage procedures. Dr. Benevenia holds medical licensure in New Jersey and is certified by the American Board of Orthopaedic Surgery in Orthopaedic Surgery. He is affiliated with Rutgers New Jersey Medical School and practices at the Practice NJMS-UH Cancer Center in Newark, NJ.

Research topics

• Medicine
• Surgery
• Engineering
• Electrical engineering
• Radiology

Selected publications

• Management of Diaphyseal Humeral Metastases

  2026-01-01

  book-chapter
  PublisherDOI

• What’s new on giant cell tumor of bone

  Springer Link (Chiba Institute of Technology) · 2026-01-22

  articleOpen access

  When treating extremities affected by giant cell tumor of bone (GCTB), curettage should be performed to preserve the joint as much as possible in order to obtain a good functional outcome. The local recurrence risk is high following curettage, but new techniques are being developed to reduce local recurrence. We present a review of the literature reporting favorable results of radiofrequency ablation alone in locally recurrent small GCTB. New filling materials are also being developed to prevent non-oncological complications such as arthrosis and fractures. Routine measurement of tartrate-resistant acid phosphatase 5b in serum may be helpful in detecting early instances of local recurrence. For unresectable or metastatic GCTB, there is an urgent need for a new drug that is as effective as denosumab, avoids side effects, and can be administered to pregnant women.

  OA PDFDOI

• Novel femoral head allograft reconstruction technique of giant cell tumor of the bone in the mid-foot: a case report

  International Journal of Research in Orthopaedics · 2026-02-24

  articleOpen accessSenior author

  An 83-year-old female presented with seven months of right medial foot swelling. Imaging revealed a lesion of the medial and middle cuneiforms with extension into the 1st and 2nd metatarsals. Biopsy suggested giant cell tumor of bone. She underwent wide excision, argon beam adjuvant, and reconstruction with a custom-molded femoral head allograft and midfoot arthrodesis. At one-year follow-up, she was pain-free, weight-bearing, and demonstrated fusion without recurrence. This case highlights a novel cement-mold technique to optimize graft fit, introducing a reconstructive strategy that maintains midfoot function despite extensive resection.

  PublisherOA PDFDOI

• What’s new on giant cell tumor of bone

  SICOT-J · 2026-01-01

  articleOpen access

  When treating extremities affected by giant cell tumor of bone (GCTB), curettage should be performed to preserve the joint as much as possible in order to obtain a good functional outcome. The local recurrence risk is high following curettage, but new techniques are being developed to reduce local recurrence. We present a review of the literature reporting favorable results of radiofrequency ablation alone in locally recurrent small GCTB. New filling materials are also being developed to prevent non-oncological complications such as arthrosis and fractures. Routine measurement of tartrate-resistant acid phosphatase 5b in serum may be helpful in detecting early instances of local recurrence. For unresectable or metastatic GCTB, there is an urgent need for a new drug that is as effective as denosumab, avoids side effects, and can be administered to pregnant women.

  PublisherOA PDFDOI

• Vanadium salt inhibits osteoclast formation and preserves bone integrity in a rat model of type-1 diabetes associated bone loss

  BioMetals · 2026-04-03

  article
  PublisherDOI

• Antibiotic Spacers Used for Prosthetic Joint Infections

  2025-01-01

  book-chapterSenior author
  PublisherDOI

• A One- or Two-Stage Revision of Fungal Prosthetic Joint Infection: A Review of Current Knowledge, Pitfalls and Recommendations

  Antibiotics · 2025-06-30 · 5 citations

  reviewOpen access

  Fungal prosthetic joint infection (fPJI) is one of the orthopaedic pathologies where there is no clear evidence, guidelines or algorithm to guide the surgeon in its management. This is in addition to the difficulty with which these infections are diagnosed, isolated and treated. Fungi form notorious biofilms that are difficult to eradicate once formed and that display resistance to antimicrobial agents. These biofilms have been shown to act synergistically with biofilms of bacteria, further adding to medical treatment resistance. We have reviewed the literature for reports that describe the results of different methods in surgically treating fPJI. We found that surgical management with two stages remains the gold standard for treatment of fPJI, as is the case for bacterial PJI (bPJI). We have investigated medical treatment, debridement with implant retention (DAIR) and staged revisions and whether a reasonable recommendation can be made based on the best knowledge and practice available. From the data on bPJI, there exists a role for conservative management of acute PJI with debridement, antibiotics and implant retention (DAIR). While fPJI and bPJI both represent infections, the differences in our ability to detect these infections clinically, culture the pathogens and treat them with proper antimicrobial agents, along with the difference in the reported results of the surgical treatment, make us believe that these two types of infections should not be treated in the same manner. With all this in mind, we reviewed several reports in the literature on fPJI to determine the efficacy of current treatment modalities, including DAIR, which followed current guidelines for PJI. Data show an overall treatment success rate of 64.4% [range 17.4-100%]. Subgroup analysis revealed a success rate of 11.6% [range 0-28.7%] in patients treated with DAIR. There is no doubt that DAIR should not be encouraged as it consistently has a bad record. Although there are not enough studies or numbers of patients to show an evidence-based preference over one- or two-staged revisions, the two-stage revision of fPJI consistently shows better results and should be considered as the gold standard of management in cases of revision fPJI. This should also be coupled with proper expertise, follow-ups and recommended lengths of medical treatment, which should not be less than six months. From the review of these data, we have developed reasonable recommendations for the management of fPJI. These recommendations center on staged surgical debridement along with medical management. Medical treatment should be for at least 6 months under the guidance of an infectious disease team and based on intraoperative cultures. In the case of local antimicrobial treatment reported in the literature, many patients with fPJI were found to have a polymicrobial infection. As a result, it is our recommendation that antifungals as well as antibacterials should be incorporated into the cement spacer mix of these cases. Fungal PJI remains an exceedingly difficult pathology to treat and should be managed by experienced surgeons in a well-equipped institution.

  PublisherOA PDFDOI

• Fungal Infections in Orthopedics

  2025-01-01

  book-chapterSenior author
  PublisherDOI

• Anemia, Abnormal Body Mass Index, and Sarcopenia Increase Complication Risk in Patients Undergoing Surgical Treatment for Metastatic Bone Disease

  Journal of Surgical Oncology · 2025-05-15 · 2 citations

  articleOpen accessSenior author

  BACKGROUND AND OBJECTIVES: Metastatic bone disease (MBD) is a common complication of primary cancers and is typically managed surgically. Overall health status and nutritional optimization are essential in surgical outcomes. The objective of this study was to report the intersectionality of previously studied laboratory, imaging, and clinical characteristics on postoperative complications. METHODS: Patients treated surgically for metastatic disease of the femur or tibia from 2001 to 2022 were reviewed. Age, gender, diagnosis, perioperative BMI, hemoglobin, albumin, method of surgical treatment, history of chemotherapy, history of radiation to the site, return to the operating room (OR), and complication type were collected for analysis. Psoas cross-sectional area was measured. RESULTS: Following review, 119 patients (61 F, 58 M) treated at 128 anatomic sites, with mean age 61.9 ± 15.6 and mean follow-up 23.7 ± 9.3 met the inclusion criteria. The rate of wound dehiscence was 7/128 (5.47%) and infection was 7/128 (5.47%). Hemoglobin < 12 [OR 1.091 (95% CI 1.023-1.164, p < 0.05)] and abnormal BMI [OR 9.000 (95% CI 0.962-84.208, p < 0.05)] were both associated with an increased risk of deep infection. Hemoglobin < 12 [OR 1.091 (95% CI 1.023-1.164, p < 0.05)] was also associated with increased risk in superficial infection. Abnormal BMI [OR 3.783 (95% CI 1.209-11.831, p < 0.05)] was associated with an increased risk of return to the OR. History of chemotherapy [OR 2.965 (95% CI 1.173-7.493, p < 0.05)] was associated with an increased risk in overall complications. There was no association found between history of diabetes and complications. No statistically significant difference was found between the method of fixation when comparing complications between those that received an endoprosthesis, intramedullary nail (IMN), or plate. CONCLUSIONS: The complication risk for patients with metastatic disease is multifactorial, with anemia, abnormal BMI, and sarcopenia as measured by psoas cross-sectional area increasing risk for nononcologic complications. In the future, large-scale studies can help quantify the impact of each factor to allow for preoperative optimization to reduce complications.

  PublisherOA PDFDOI

• Binding of zinc to processed human bone allograft and potential use of zinc as an anti-microbial agent

  Exploration of BioMat-X · 2025-07-07 · 1 citations

  articleOpen access

  Aim: Zinc is essential for normal bone growth and can promote bone regeneration. Processed human bone allograft treated with zinc shows improved bone formation activity. Various factors were tested for effects on zinc binding to bone allograft with the long-term goal of developing methods to enhance the bone formation activity and safety of bone allograft in orthopaedic applications. Methods: The amount of zinc bound to allograft was measured using Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). Fluorescent visualization of zinc bound to allograft was accomplished using Zinpyr-1. The potential anti-microbial property of zinc-treated allograft was measured by exposing allograft to Staphylococcus aureus. After washing, the exposed allograft was cultured in bacterial media to measure residual Staphylococcus aureus. Data were analyzed using standard parametric methods. Results: Rapid binding of zinc to bone allograft (1–15 min) was relatively insensitive to zinc concentration, incubation time, pH, or divalent cation competition. In contrast, zinc salt counter ions had significant effects, with zinc acetate producing more rapid zinc binding than zinc chloride or zinc picolinate. The ability of Staphylococcus aureus to contaminate bone allograft was also significantly reduced by prior zinc treatment. Conclusions: The study results provide guidelines for modifying the processing of bone allograft to enhance bone formation activity while also improving the resistance of the allograft to bacterial contamination.

  PublisherOA PDFDOI

Frequent coauthors

• Kathleen S. Beebe

  Rutgers New Jersey Medical School

  135 shared

• Francis Patterson

  Hackensack University Medical Center

  111 shared

• Joseph A. Ippolito

  Rutgers New Jersey Medical School

  90 shared

• Meera Hameed

  73 shared

• Sheldon S. Lin

  56 shared

• S Rivero

  46 shared

• Marcia F. Blacksin

  Rutgers, The State University of New Jersey

  40 shared

• Seena C. Aisner

  38 shared

Education

• M.D.

  UMDNJ - New Jersey Medical School

  1984

• B.A.

  Saint Louis University, Missouri

  1980